ProAlgaZyme Novel Algae Infusion: Applications in Immunodeficiency
Status:
Completed
Trial end date:
2006-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and effects in HIV patients of
supplementation (4-20 fl. oz. daily) with ProAlgaZyme, a novel fermentation product of a
freshwater algae ecosystem, on markers of immune status, dyslipidemia, inflammation and
oxidative stress alone or in combination with HAART (highly-active antiretroviral therapy).